poisar

Stocks · News reference

JP Morgan Maintains Overweight on Septerna, Raises Price Target to $48

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SEPN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Septerna to Participate in Upcoming Investor Conferences

    Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company focused on GPCR drug discovery, announced participation in two investor conferences in September 2026. The company also appointed industry veteran Rajiv Patni, M.D., as Chief Medical Officer. Septerna is advancing its Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist, with SAD/MAD data expected in Q1 2027.

    SEPN
  2. SEC EDGAR

    8-K filing — Septerna, Inc. (SEPN)

    Filed: 2026-08-25 AccNo: 0001193125-26-364210 Size: 154 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    SEPN